Islatravir

Generic Name: Islatravir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₂FN_₅O_₃

CAS Number: 865363-93-5

Unique Ingredient Identifier: QPQ082R25D

Background: Islatravir is under investigation in clinical trial NCT04233216 (Doravirine/islatravir (DOR/ISL) in Heavily Treatment-experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Phase 2

Active, not recruiting

Conditions: HIV-1 Infection

Interventions: Drug: Islatravir
Drug: BIC/FTC/TAF
Drug: Ulonivirine
Drug: Placebo to ISL
Drug: Placebo to Ulonivirine
Drug: Placebo to BIC/FTC/TAF

First Posted Date: 2020-09-25

Last Posted Date: 2025-01-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 161

Registration Number: NCT04564547

Locations: 🇺🇸
Men's Health Foundation ( Site 2710), Los Angeles, California, United States
🇺🇸
Kansas City CARE Clinic ( Site 2703), Kansas City, Missouri, United States
🇺🇸
Chatham County Health Department ( Site 2707), Savannah, Georgia, United States

and more 20 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy